Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...

(RTTNews) - Third Harmonic Bio, Inc. (THRD), a clinical-stage biopharmaceutical company, on Tuesday announced promising results from its Phase 1 clinical trial of THB335, a potent and selective ...

Third Harmonic plans to file a U.S. IND and initiate clinical development of THB335 for the treatment of mast cell-mediated inflammatory diseases during the first half of 2024. The company also ...

These data are expected to support the advancement of THB335 into a Phase 2 clinical trial in chronic spontaneous urticaria (CSU). The Company is initiating a strategic review process to run in ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data ...

Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps THB335 Phase 1 Clinical Results The Phase 1 SAD ...